Sweden · Delayed Price · Currency is SEK Xbrane Biopharma AB Statistics
Total Valuation
STO:XBRANE has a market cap or net worth of SEK 267.87 million. The enterprise value is 294.39 million.
| Market Cap | 267.87M |
| Enterprise Value | 294.39M |
Important Dates
The last earnings date was Friday, October 30, 2026.
| Earnings Date | Oct 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
STO:XBRANE has 20.61 million shares outstanding. The number of shares has decreased by -98.94% in one year.
| Current Share Class | 20.61M |
| Shares Outstanding | 20.61M |
| Shares Change (YoY) | -98.94% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 5.42% |
| Owned by Institutions (%) | -1.54% |
| Float | 17.36M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.28 |
| PB Ratio | 0.55 |
| P/TBV Ratio | 1.46 |
| P/FCF Ratio | 4.32 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.49 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 4.71 |
Financial Position
The company has a current ratio of 3.21, with a Debt / Equity ratio of 0.12.
| Current Ratio | 3.21 |
| Quick Ratio | 0.66 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.95 |
| Interest Coverage | -9.69 |
Financial Efficiency
Return on equity (ROE) is -11.10% and return on invested capital (ROIC) is -8.16%.
| Return on Equity (ROE) | -11.10% |
| Return on Assets (ROA) | -4.27% |
| Return on Invested Capital (ROIC) | -8.16% |
| Return on Capital Employed (ROCE) | -8.53% |
| Weighted Average Cost of Capital (WACC) | 7.80% |
| Revenue Per Employee | 4.41M |
| Profits Per Employee | -2.16M |
| Employee Count | 29 |
| Asset Turnover | 0.19 |
| Inventory Turnover | 0.62 |
Taxes
In the past 12 months, STO:XBRANE has paid 89,000 in taxes.
| Income Tax | 89,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +34.38% in the last 52 weeks. The beta is 0.73, so STO:XBRANE's price volatility has been lower than the market average.
| Beta (5Y) | 0.73 |
| 52-Week Price Change | +34.38% |
| 50-Day Moving Average | 11.36 |
| 200-Day Moving Average | 9.92 |
| Relative Strength Index (RSI) | 55.31 |
| Average Volume (20 Days) | 221,886 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, STO:XBRANE had revenue of SEK 127.95 million and -62.68 million in losses. Loss per share was -3.04.
| Revenue | 127.95M |
| Gross Profit | 19.82M |
| Operating Income | -45.14M |
| Pretax Income | -61.76M |
| Net Income | -62.68M |
| EBITDA | -48.48M |
| EBIT | -45.14M |
| Loss Per Share | -3.04 |
Balance Sheet
The company has 37.41 million in cash and 63.93 million in debt, with a net cash position of -26.52 million or -1.29 per share.
| Cash & Cash Equivalents | 37.41M |
| Total Debt | 63.93M |
| Net Cash | -26.52M |
| Net Cash Per Share | -1.29 |
| Equity (Book Value) | 527.15M |
| Book Value Per Share | 25.58 |
| Working Capital | 196.33M |
Cash Flow
In the last 12 months, operating cash flow was -76.80 million and capital expenditures 144.30 million, giving a free cash flow of 67.50 million.
| Operating Cash Flow | -76.80M |
| Capital Expenditures | 144.30M |
| Depreciation & Amortization | -3.35M |
| Net Borrowing | 56.65M |
| Free Cash Flow | 67.50M |
| FCF Per Share | 3.28 |
Margins
Gross margin is 15.49%, with operating and profit margins of -35.28% and -48.99%.
| Gross Margin | 15.49% |
| Operating Margin | -35.28% |
| Pretax Margin | -48.27% |
| Profit Margin | -48.99% |
| EBITDA Margin | -37.89% |
| EBIT Margin | -35.28% |
| FCF Margin | 52.76% |
Dividends & Yields
STO:XBRANE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 98.94% |
| Shareholder Yield | 98.94% |
| Earnings Yield | -23.40% |
| FCF Yield | 23.15% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 17, 2025. It was a reverse split with a ratio of 0.008.
| Last Split Date | Oct 17, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.008 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |